Eicosanoids, β-cell function, and diabetes

P Luo, MH Wang - Prostaglandins & other lipid mediators, 2011 - Elsevier
Arachidonic acid (AA) is metabolized by cyclooxygenase (COX), lipoxygenase (LOX), and
cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in diverse diseases …

Pharmacogenetics and personalized treatment of type 2 diabetes

S Semiz, T Dujic, A Causevic - Biochemia medica, 2013 - hrcak.srce.hr
Sažetak Type 2 diabetes mellitus (T2DM) is a worldwide epidemic with considerable health
and economic consequences. T2DM patients are often treated with more than one drug …

Evaluation of the impact of vindoline, an active components of Catharanthus roseus, on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs

Y Zhang, H Niu, J Liu, W Xie, Y Jin, Z Zhang - Plos one, 2023 - journals.plos.org
The objection of this study was to investigate the effects of vindoline (VDL) on the
cytochrome P450 (CYP 450) isoforms (CYP1A2, 2B, 2C11, 2D1 and 3A) in rats. Firstly, the …

Perceptions of students in health and molecular life sciences regarding pharmacogenomics and personalized medicine

L Mahmutovic, B Akcesme, C Durakovic, FB Akcesme… - Human Genomics, 2018 - Springer
Background Increasing evidence is demonstrating that a patient's unique genetic profile can
be used to detect the disease's onset, prevent its progression, and optimize its treatment …

Genotypic and phenotypic factors influencing drug response in Mexican patients with type 2 diabetes mellitus

HE Sanchez-Ibarra, LM Reyes-Cortes… - Frontiers in …, 2018 - frontiersin.org
The treatment of Type 2 Diabetes Mellitus (T2DM) consists primarily of oral antidiabetic
drugs (OADs) that stimulate insulin secretion, such as sulfonylureas (SUs) and reduce …

[PDF][PDF] Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina

A Ašić, R Salazar, S Doğan, W Höppner… - Croatian medical …, 2019 - hrcak.srce.hr
Aim To investigate the prevalence of common genetic variants that can serve as markers of
thrombophilia and warfarin pharmacogenetics in Bosnia and Herzegovina. Methods The …

Analysis of the Potential Association of Drug-metabolizing Enzymes CYP2C9∗ 3 and CYP2C19∗ 3 Gene Variations with Type 2 Diabetes: A Case-control Study

I Elfaki, R Mir, FM Abu-Duhier, CK Jha… - Current Drug …, 2020 - ingentaconnect.com
Background: Cytochrome P450s (CYPs) are drug-metabolizing enzymes catalyzing the
metabolism of about 75% of drug in clinical use. CYP2C9 represents 20% CYP proteins in …

The genetics of adverse drug outcomes in type 2 diabetes: A systematic review

AM Baye, TG Fanta, MK Siddiqui, AY Dawed - Frontiers in Genetics, 2021 - frontiersin.org
Background: Adverse drug reactions (ADR) are a major clinical problem accounting for
significant hospital admission rates, morbidity, mortality, and health care costs. One-third of …

Genetic variation of CYP2C9 gene and its correlation with cardiovascular disease risk factors

GS Rasool, SJ Al-Awadi, AA Hussien… - Molecular Biology …, 2024 - Springer
Background The major enzyme that is responsible for Sulfonylureas (SUs) metabolism is
hepatic cytochrome P-450 2C9 (CYP2C9). It is encoded by the polymorphic gene CYP2C9 …

Association of CYP7A1 and CYP2E1 Polymorphisms with Type 2 Diabetes in the Chinese Han Populations

L Zhang, J Tang, Y Wang, X Wang… - Pharmacogenomics and …, 2022 - Taylor & Francis
Background Type 2 diabetes mellitus (T2DM) is caused by diverse environmental and
genetic risk factors. Previous studies have reported that cytochrome P450 (CYP) is a …